Stomach specific floating drug delivery system: A review

International Journal of PharmTech Research

Volumn 1, Issue 3, 2009, Pages 623-633

  Shah, S H ^a   Patel, J K ^b   Patel, N V ^c  

^a GUJARAT UNIVERSITY   (India)

^b GANPAT UNIVERSITY   (India)

^c SARDAR PATEL UNIVERSITY   (India)

Author keywords

Effervescent; Floating drug delivery system; Gastric residence time; Hydrodynamically balanced system; Non effervescent

Indexed keywords

4 NITROANILINE; ACETYLSALICYLIC ACID; CAPTOPRIL; CIPROFLOXACIN; CLARITHROMYCIN; DA 6034; FLAVONOID; FUROSEMIDE; GRISEOFULVIN; INDOMETACIN; METRONIDAZOLE; NIMODIPINE; PIROXICAM; PROPRANOLOL; TETRACYCLINE; UNCLASSIFIED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; BULK DENSITY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; ENCAPSULATION; GASTRITIS; HUMAN; HYDRODYNAMICS; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; NONHUMAN; REVIEW; STOMACH EMPTYING; STOMACH ULCER; TABLET FRIABILITY; TABLET HARDNESS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77953440590     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Wilson C.G, Washington N., Physiological Pharmaceutics: Biological Barriers to Drug Absorption, Horwood Ellis, Chichester,1989,47-70
2. Singh B.M and Kim K. H., Floating drug delivery systems: an approach to controlled drug delivery via gastric retention. Cont. J. Rel. 2000, 63,235-259.
3. Deshpande A.A., Shah N.H., Rhodes C.T., Malick W., Development of a novel controlled-release system for gastric retention, Pharm. Res. 1997,14,815-819
4. Kawashinia Y, Niwa T. Takcuchi H. Hino T, Itoh Y. Hallow microspheres for use as a floating controlled drug delivery system in the stomach. J.Pharm. Sci.1992, 81(2), 135-140.
5. Ichikawa M., .Watemblc S., Miyake V.A. Multiple unit oral floating dosage systems I: Preparation and in-vivo evaluation of' floating and sustained release characteristics. J.Pharm. Sci. l99l, 80,l062-1066
6. Sato Y, Kawaafaima Y., Takenchi H. Invitro and in vivo evaluation of riboflavin containing microoballoons for floating controlled delivery system in healthy humans. Int. J.Pharm. 2004, 275,75-82
7. Washington N., Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon, Drug Investig. 1987,2,23-30.
8. Foldager J., Toftkjor H., Antacid composition. US Patent 5068109, 1991,
9. Fabrcgas J.L, Cucala C.G., Pous J., Sites R.A. In vitro testing of an antacid formulation with prolonged gastric residence time. Drug Dev. Ind. Pharm. 1994,20,1199-1212
10. Ponchel G., Irache J.M. Specific and non-specific bioadhesive particulate system for Oral delivery to the gastrointestinal tract. Adv.Drug.Del.Rev.1998; 34:191-219.
11. Redniek. A.B, Tucker S.J. Sustained release bolus for animal husbandry US Patent 3,507,952, 1970.
12. Bechgaard H., Ladefoged K. Distribution of pellets in the gastrointestinal tract: The influence on transit time exerted by density or diameter of pellets. J.Pharm. Pharmacol. 1978,30,690-692.
13. Davis S.S, Stockwell S.F, Taylor M.J, Hardy J.G, Whelley D.R, The effect on density on the gastric emptying of Single and multiple-unit dosage form. Pharm.Res.1986, 3,208-213.
14. Hwang S.J., Park H.. Gastric retentive drug-delivery systems. Cri.Rev.Ther.DrugCarr.Syst.1998, 15,234-284.
15. Ito R., Mchida Y., Sannan T., Nagai T.. Magnetic granules: a novel system for specific drug delivery to oesophageal mucosa in oral administration. Int. J. Pharm. 1990,61,109-117
16. Fujimori J. Machida Y., Nagai T. Preparation of magnetically-responsive tablet and confirmation of its gastric residence in beagle dogs. STP Pharm.Sci. l994, 4,425-430.
17. Griming R., Berntgen M. Estimation of the gastric residence time magnetic dosage forms using the Heidlberg capsule. Pharmazie. 1996,51,328-331
18. Reddy L.H, Murthy R.H, Floating dosage systems in drug delivery, Crit.Rev. Ther. Drug Carr. Syst. 2002, 19(6), 553-585
19. Garg S. and Sharma S. Gastroretentive Drug Delivery System, Business Briefing: Pharmatech. 2003, 160-166.
20. Rubinstein A., Friend D.R, Specific delivery to the gastrointestinal tract, in: Domb A.J (Ed.), Polymeric Site-Specific Pharmacotherapy, Wiley, Chichester, 1994, 282-283.
21. Ozdemir N., Ordu S, OzkanY. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev. Ind. Pharm. 2000,26,857-866
22. Penners G.,Lustig K., .Jorg P.V.G. Expandable pharmaceutical forms. US patent 5,651,985, 1997
23. Talwar N., .Sen H., Staniforth J.N, Orally administered controlled drug delivery system providing temporal and spatial control. US patent 6261601, 2001
24. Sheth P.R. and Tossounian J.L. U.S. Patent no.4140755, 1979.
25. Roy H.M, U.S. Patent no. 4055178, 1977
26. Whitehead L.., .Fell J., Sharma H.L. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J.cont. Rel. 1998,55:3-12
27. Sato Y., Kawashima Y. Physicochemical properties to determine the buoyancy of hollow microspheres (microballoons) prepared by the emulsion solvent diffusion method. Eur. J. Pharm. Sci. 2003,55:297-304
28. Joseph N.H. Laxmi S., Jayakrishnan A. A floating type oral dosage from for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J. Cont. Rel. 2002; 79:71-79.
29. Yang L., Fassihi R. Zero order release kinetics from self correcting floatable configuration drug delivery system. J. Pharm. Sci. 1996;85:170-173
30. Yang L., Esharghi J., Fassihi R. A new intra gastric delivery system for the treatment of helicobacter pylori associated gastric ulcers: in vitro evaluation. J. Cont. Rel. 1999; 57:215-222.
31. Streubel A., Siepmann J., Bodmeier R. Floating matrix tablets based on low density foam powder: effect of formulation and processing parameters on drug release. Eur. J. Pharm. Sci. 2003;18:37-45
32. Wu W, Zhou Q, Zhang H.B, Ma G.D, Fu C.D. Studies on Nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident time. Yao Xue Xue Bao. 1997;32:786-790
33. Nur A.O, Zhang J.S. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev. Ind. Pharm. 2000; 26:965-969.
34. Iannuccelli V, Coppi G., Sansone R., Ferolla G., Air compartment multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation, Int. J. Pharm. 174 (1998) 55-62.
35. Tardi P., Troy H., European patent no. EP 1432402. 2002
36. Ikura, Hiroshi, Suzuki, Yoshiki United States Patent 4777033.1988
37. Umezawa, Hamao United States Patent 4101650.1978
38. Iannuccelli V., Coppi G., Bernabei M.T. and Cameroni R., Air compartment multiple-unit system for prolonged gastric residence. Part I. Formulation study, Int.J.Pharm. 1998,174, 47-54
39. Stops F., Fell J.T., Collett J.H., Martini L.G. Floating dosage forms to prolong gastroretention - the characterisation of calcium alginate beads, Int. J. Pharm. 2008, 350,301-311
40. Ichikawa M., Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Prepration and in vitro evaluation of floating and sustained-release kinetics. J. Pharm.Sci. 1991; 80:1062-1066.
41. Thanoo B.C, Sunny M.C. and Jayakrishnan A., Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid, J. Pharm. Pharmacol. 1993,45,21-24.
42. Sato Y., Kawashima Y., Takeuchi H. and Yamamoto H., In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers, J. Cont. Rel. 2003, 93, 39-47.
43. El-Kamel A.H., Sokar M.S, Algamal S.S, Naggar V.F. Preparation and evaluation of ketoprofen floating oral drug delivery system. Int. J. Pharm. 2001;220:13-21
44. Kawashima Y., Niwa T., Takeuchi H., Hino T., ItoY. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resins containing tranilast and their drug release characteristics (in vivo). J. Cont. Rel. 1991; 16:279-290.
45. Jayanthi G., Jayaswal S.B., Srivastava A.K. Formulation and evaluation of terfenadine microballoons for oral controlled release. Pharmazie. 1995; 50:769-770.
46. Gu T.H. et al. Pharmacokinetics and pharmacodynamics of diltiazem floating tablets. Chung Kao Yao Li Hsuesh Pao. 1992;13:527-531
47. Ichikawa M., Watanabe S., Miyake Y. A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustainedrelease characteristics with para amino benzoic acid and isosorbide dinitrate as model drugs. J. Pharm. Sci. 1991;80:1153-1156
48. Rouge N., Cole E.T., Doelker E., Buri P. Buoyancy and drug release patterns of floating mini tablets containing piretanide and atenolol as model drugs. Pharm. Dev. Technol. 1998; 3:73-84.
49. Cheuh H.R., Zia H., Rhodes C.T. Optimization of Sotalol floating and bioadhesive extended release tablet formulation. Drug Dev. Ind. Pharm. 1995;21:1725-1747
50. Gustafson J.H., Weissman L., Weinfeld R.T. et al. Clinical bioavailability evaluation of a controlled release formulation of diazepam. J. Pharmacokinet. Biopharm. 1981;9:679-691
51. Simoni P., Cerre C., Cipolla A., et al. Bioavailabilty study of a new sinking, enteric coated ursodeoxycholic acid formulation. Pharmacol. Res. 1995;31:115-119
52. http://www.drugdeliverytech.com/ME2/dirm od.asp?sid= 4306B1E9C3CC4E07A4D64E23F BDB232Candnm=Back+Issuesandtype=Publis hingandmod=Publications%3A%3AArticleand mid=8F3A7027421841978F18BE895F87F791 andtier=4andid=CC1CDA11871540EFAFAB5 0839AFFD292
53. Karande A.D., Yeole P.G. Comparative Assessment of Different Dissolution Apparatus for Floating Drug Delivery Systems. Dissolutiontech, (2006),13(1),20-23
54. Gohel M.C., Mehta P.R.., Dissolutiontech. 2004,11(4),22-25
55. Agnihotri S.A., Jawalkar S.S. and Aminabhavi T.M., Controlled release of cephalexin through gellan gum beads: Effect of formulation parameters on entrapment efficiency, size, and drug release, Eur. J. Pharm. Biopharm. 63 (2006) 249-261
56. Fell J., Digenis C.G. Imaging and behaviour of solid oral dosage forms in vivo. Int.J.Pharm.1984,22(1),1-15
57. Harries D., .Sharma H.L. GI transit of potential bioadhesive formulations in man: A scintigraphic study. J.Cont.Rel. 1990,12(1),45-53
58. Timmermans J.,Gansbeke V.B., .Moes A.J.. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Vol I. Proceedings of the 5th International Conference on Pharmacy Technology. Paris, France: APGI, 1989:42-51
59. Sawicki W. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur. J. Pharm. Biopharm. 2002; 53:29-35.
60. Ninan M., Lu X., Wanga Q., Zhanga X. Development and evaluation of new sustained-release floating microspheres, Int.J.Pharm. 2008, 358,82-90
61. 2 generation by benchtop MRI and its relation to drug release and floating strength. European J.Pharm.and Biopharm. 2008,69,708-717
62. Janga S., Lee J., Park S. Gastroretentive drug delivery system of DA-6034, a new flavonoid derivative, for the treatment of gastritis. Int.J.Pharm. 2008,356,88-94
63. Sungthongjeena S. Sriamornsak P. and Puttipipatkhachorn S. Design and evaluation of floating multi-layer coated tablets based on gas formation. Euro. J. Pharm. and Biopharm. 2008,69,255-263
64. Rajinikanth P. and Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H.pylori, J.Cont.Rel. 2008, 25, 33-41